Vantage Concludes a Landmark APAC Gala Dinner in Vietnam, Celebrating Regional Excellence and a Bold Vision for 2026
PORT VILA, Vanuatu, Dec. 15, 2025 /PRNewswire/ -- Vantage proudly concluded its…
CGTN: How does China set tone for economic work in 2026?
BEIJING, Dec. 12, 2025 /PRNewswire/ -- With Chinese leaders gathered in Beijing…
12TH ANNUAL WINTERNATIONAL EMBASSY SHOWCASE DRAWS 8,000 GUESTS
70 Embassies Unite to Celebrate Global Culture and Traditions at the Ronald…
2025 in Review: Celebrating Each Trader’s Unique Journey on Bybit
DUBAI, UAE, Dec. 11, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency…
Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025 21:04 ET Â | Source: InnoCare Pharma BEIJING, Dec. 08,…
ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET Â | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Yidan Prize Foundation connects global insights and local expertise at annual flagship Summit
500 changemakers from over 50 countries stand in solidarity with Hong Kong…
NYSE Content Advisory: Pre-Market Update + NYSE Hosts 102nd Annual Tree Lighting
NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The New York Stock Exchange…